{"Clinical Trial ID": "NCT02441946", "Intervention": ["INTERVENTION 1:", "Abemaciclib + Anastrozole", "Participants received 150 mg of oral abemaciclib Q12H plus 1 mg of oral anastrozole QD for 2 weeks.", "All participants received 150 mg of oral abemaciclib Q12H plus 1 mg of oral anastrozole QD for an additional 14 weeks.", "The total duration of treatment was 16 weeks.", "INTERVENTION 2:", "Abemaciclib", "Participants received 150 mg of oral abemaciclib Q12H for 2 weeks.", "All participants received 150 mg of oral abemaciclib Q12H plus 1 mg of QD anastrozole for an additional 14 weeks.", "The total duration of treatment was 16 weeks."], "Eligibility": ["Incorporation criteria:", "Have a postmenopausal status.", "Adenocarcinoma of the breast.", "1 centimetre (cm) diameter breast tumour, HR+, HER2-.", "Endocrine neoadjuvant monotherapy is considered an appropriate therapy.", "The primary breast cancer that is suitable for basic biopsy.", "To have an adequate organ function.", "- Exclusion criteria:", "Invasive bilateral breast cancer.", "- Metastatic breast cancer (local spread to axillary lymph nodes is permitted).", "Inflammatory breast cancer.", "A systemic treatment or prior radiation therapy for invasive or non-invasive breast cancer in the same breast as is currently being treated.", "A radiotherapy prior to the ipsilateral chest wall for any malignancy.", "A prior estrogen treatment."], "Results": ["Performance measures:", "Percentage change in reference level at 2 weeks in Ki67", "The tumour tissue collected during a basic biopsy and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percentage of positive cell spots by validated central assay.", "Time frame: baseline, 2 weeks", "Results 1:", "Title of the arm/group: Abemaciclib + Anastrozole", "Description of the arm/group: Participants received 150 mg of oral abemaciclib Q12H plus 1 mg of oral anastrozole QD for 2 weeks.", "All participants received 150 mg of oral abemaciclib Q12H plus 1 mg of oral anastrozole QD for an additional 14 weeks.", "The total duration of treatment was 16 weeks.", "Total number of participants analysed: 59", "Geometric mean (90% confidence interval)", "Unit of measure: Percentage change -92.86 (-94.82 to -90.16)", "Results 2:", "Title of the arm/group: Abemaciclib", "Description of the arm/group: Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.", "All participants received 150 mg of oral abemaciclib Q12H plus 1 mg of QD anastrozole for an additional 14 weeks.", "The total duration of treatment was 16 weeks.", "Total number of participants analysed: 52", "Geometric mean (90% confidence interval)", "Unit of measure: Percentage change -90.52 (-93.12 to -86.93)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/74 (1.35%)", "Neutropenia 0/74 (0.00 %)", "Acute coronary syndrome 0/74 (0.00 %)", "Angine pectoris 0/74 (0.00 %)", "Myocardial infarction 0/74 (0.00 %)", "Abdominal pain 1/74 (1.35%)", "- Pancreatitis 0/74 (0.00 %)", "- Mastitis 0/74 (0.00 %)", "- Fracture 0/74 (0.00 %)", "Increased alanine aminotransferase 1/74 (1.35%)", "Increased aspartate aminotransferase 1/74 (1.35%)", "Adverse Events 2:", "Total: 1/75 (1.33%)", "Neutropenia 0/75 (0.00 %)", "Acute coronary syndrome 0/75 (0.00 %)", "Angine pectoris 0/75 (0.00 %)", "Myocardial infarction 0/75 (0.00 %)", "Abdominal pain 0/75 (0.00 %)", "Pancreatitis 0/75 (0.00 %)", "- Mastitis 0/75 (0.00 %)", "Fracture 0/75 (0.00 %)", "Increased alanine aminotransferase 0/75 (0.00 %)", "Increased aspartate aminotransferase 0/75 (0.00 %)"]}